A 45-year-old woman presents to her GP with a painful, red, swollen area on her lower leg that has developed over 48 hours. This scenario exemplifies the bread-and-butter of infectious diseases practice in the UK, where skin and soft tissue infections account for approximately 10% of hospital admissions. Understanding the epidemiology and microbiology of common infections is essential for appropriate empirical therapy and effective antimicrobial stewardship . Community-acquired infections differ fundamentally from healthcare-associated infections in their causative organisms and resistance patterns.
Key Infection Categories and Epidemiology:
Community-acquired infections: Most commonly caused by Streptococcus pyogenes (Group A Strep), Staphylococcus aureus (MSSA), and Escherichia coli
Healthcare-associated infections (HAIs): Defined as infections occurring ≥48 hours after hospital admission
Antibiotic resistance patterns in the UK:
| Infection Type | Leading Pathogen | Second Most Common | Key Risk Factor |
|---|---|---|---|
| Cellulitis | Streptococcus pyogenes | Staphylococcus aureus | Lymphoedema, obesity |
| Surgical site infection | Staphylococcus aureus | Coagulase-negative staphylococci | Prolonged surgery >2h |
| Diabetic foot infection | Polymicrobial | S. aureus + anaerobes | Neuropathy, PVD |
| Hospital-acquired pneumonia | Pseudomonas aeruginosa | MRSA | Mechanical ventilation |
📌 Mnemonic for Cellulitis Risk Factors: "LOVED" - Lymphoedema, Obesity, Venous insufficiency, Eczema/dermatitis, Diabetes

Understanding how bacteria breach the skin's protective barrier helps explain why certain patients develop severe infections while others remain unaffected. In cellulitis, Streptococcus pyogenes produces hyaluronidase and streptokinase, enzymes that break down connective tissue and allow rapid spread through tissue planes. The host inflammatory response-mediated by cytokines like IL-1 and TNF-α-causes the characteristic erythema, warmth, and oedema. This pathophysiological insight underpins why anti-inflammatory measures alone fail and why early antibiotic therapy targeting streptococci is critical in managing skin and soft tissue infections .
Key Pathophysiological Mechanisms:
Bacterial virulence factors:
Host defence breakdown:
Clinical Presentations by Depth:
Superficial infections (epidermis/dermis):
Deep infections (subcutaneous tissue):
A 68-year-old man with type 2 diabetes presents with a 3-day history of right leg pain, erythema extending from ankle to knee, and fever. His observations show temperature 38.7°C, heart rate 105 bpm, blood pressure 128/82 mmHg. NICE guideline NG141 recommends using the Eron classification to guide management decisions for cellulitis . This systematic approach, integrated with antimicrobial stewardship principles , ensures appropriate treatment intensity while minimising unnecessary hospital admissions.
Diagnostic Investigations:
Bedside tests:
Laboratory investigations:
Imaging (when diagnostic uncertainty):
| Eron Class | Systemic Features | Comorbidities | Management Setting | Antibiotic Route |
|---|---|---|---|---|
| I | None | None | Community | Oral |
| II | None | Present (diabetes, obesity) | Community | Oral |
| III | Present (fever, tachycardia) | ± comorbidities | Hospital | IV initially |
| IV | Sepsis or limb-threatening | Any | Hospital + surgical | IV + surgery |

Distinguishing cellulitis from its mimics prevents inappropriate antibiotic use-a cornerstone of antimicrobial stewardship . Up to 30% of suspected cellulitis cases are misdiagnosed, leading to unnecessary antibiotics and delayed appropriate treatment. Key differentiators include unilateral versus bilateral presentation, presence of systemic features, and specific clinical signs.
Critical Discriminators:
Cellulitis versus venous eczema/stasis dermatitis:
Cellulitis versus DVT:
Treatment failure causes in skin and soft tissue infections :
| Feature | Cellulitis | Venous Eczema | DVT | Necrotising Fasciitis |
|---|---|---|---|---|
| Onset | Acute (<3 days) | Chronic/subacute | Acute | Hyperacute (<24h) |
| Laterality | Unilateral | Usually bilateral | Unilateral | Unilateral |
| Pain severity | Moderate | Mild | Moderate | Severe (out of proportion) |
| Systemic features | Present | Absent | Absent | Severe (shock) |
| CRP | >50 mg/L | <10 mg/L | <20 mg/L | >150 mg/L |
🚩 Red Flag: Pain out of proportion to clinical findings + rapidly progressive erythema + systemic toxicity = necrotising fasciitis until proven otherwise. LRINEC score ≥6 suggests necrotising infection (sensitivity 68%, specificity 85%).
NICE guideline NG141 recommends flucloxacillin as first-line empirical therapy for cellulitis, targeting the most common pathogens (streptococci and staphylococci). The choice reflects local antimicrobial resistance patterns and the principle of using narrow-spectrum agents when possible-central to antimicrobial stewardship . Treatment duration should be the minimum effective period, typically 5-7 days for uncomplicated cellulitis, with clinical response (defervescence, reduced erythema) guiding decisions rather than arbitrary completion of courses.
First-Line Empirical Therapy:
Cellulitis (non-purulent):
Cellulitis near eyes/nose (risk of MRSA):
De-escalation principles:
| Clinical Scenario | First-Line Antibiotic | Dose | Duration | MRSA Cover Needed? |
|---|---|---|---|---|
| Uncomplicated cellulitis | Flucloxacillin | 500mg QDS PO | 5-7 days | No |
| Severe cellulitis (Class III) | Flucloxacillin | 1-2g QDS IV | Until afebrile 24h, then switch PO | No |
| Diabetic foot infection | Co-amoxiclav | 625mg TDS PO | 7 days | Consider if recent healthcare contact |
| Post-surgical wound | Flucloxacillin + gentamicin | 2g QDS IV + 5mg/kg OD IV | Review at 48h | Yes if high risk |
⭐ Clinical Pearl: If cellulitis not improving after 48h of flucloxacillin, consider: (1) Is it really cellulitis? (2) Is there an abscess needing drainage? (3) Is MRSA or Gram-negative cover needed? Avoid reflexive escalation without reassessing diagnosis.
A 72-year-old woman with recurrent cellulitis (fourth episode in 18 months) presents a stewardship challenge: does she need prophylactic antibiotics? NICE NG141 recommends prophylaxis only after ≥2 episodes in 12 months, using phenoxymethylpenicillin 500mg OD-BD for at least 6-12 months. This approach, integrating principles from antimicrobial stewardship and understanding of skin and soft tissue infections , balances infection prevention against antibiotic resistance risks.
Recurrent Cellulitis Management:
Identify and address predisposing factors:
Prophylactic antibiotic criteria (NICE NG141):
Stewardship Audit Metrics:
| Stewardship Intervention | Implementation Strategy | Expected Impact | Measurement |
|---|---|---|---|
| Clinical decision support | Electronic alert for cellulitis diagnosis suggesting flucloxacillin | Increase guideline compliance by 25% | Audit prescribing data |
| IV-to-oral switch protocol | Pharmacy-led review at 48-72h | Reduce IV antibiotic days by 30% | Total IV days per admission |
| Diagnostic stewardship | Mandatory CRP for suspected cellulitis | Reduce inappropriate antibiotics by 15% | Prescriptions for cellulitis mimics |
| Prophylaxis review | Annual assessment of ongoing need | Reduce unnecessary prophylaxis by 20% | Patients on prophylaxis >12 months |
Key Take-Aways:
Essential Common Infections Numbers:
| Parameter | Value | Clinical Significance |
|---|---|---|
| Cellulitis incidence | 200 per 100,000/year | Common presentation in primary and secondary care |
| CRP threshold | >50 mg/L | Supports bacterial cellulitis diagnosis |
| WCC in cellulitis | >15×10⁹/L | Suggests significant bacterial infection |
| Treatment duration | 5-7 days | Minimum effective period for uncomplicated cases |
| Recurrence rate | 8-20% within 3 years | Justifies prophylaxis consideration |
| MRSA bloodstream prevalence | ~5% | Low; routine MRSA cover not needed |
Key Principles:
Quick Reference:
| Clinical Question | Answer |
|---|---|
| First-line antibiotic for cellulitis? | Flucloxacillin 500mg-1g QDS PO |
| When to admit? | Eron Class III/IV (systemic features or limb-threatening) |
| When to add MRSA cover? | Periorbital/perinasal location, recent healthcare contact, known MRSA carrier |
| Treatment duration? | 5-7 days (uncomplicated); extend if slow response |
| Prophylaxis indication? | ≥2 episodes in 12 months |
| Red flag for necrotising infection? | Pain out of proportion + rapid progression + systemic toxicity |
Test your understanding with these related questions
A 65-year-old man with diabetes presents with a non-healing foot ulcer for 3 months. X-ray shows osteolytic changes in the underlying bone. MRI confirms osteomyelitis. What is the most appropriate treatment duration for antibiotics?
Get full access to all lessons, practice questions, and more.
Start Your Free Trial